

THE ACTIV-2 STUDY

WE CAN RISE ABOVE COVID-19 BUT WE CAN'T DO IT WITHOUT YOU



The ACTIV-2 Study is funded by the National Institutes of Health and conducted by the AIDS Clinical Trials Group (ACTG). The aim of the study is to find safe and effective treatments for early COVID-19. Currently, there are no proven treatments for people who have symptomatic COVID-19, but are not sick enough to be in the hospital.

We are reaching out to make you aware of the study as you may be able to identify eligible patients and help in the global effort to find a treatment for COVID-19.

STUDY POPULATION

People age 18 and older who:

- Tested positive for COVID-19 (no more than 7 days ago)
- Not hospitalized
- Have COVID-19 symptoms:
 - For not more than 10 days
 - At least 1 symptom within the last 2 days
 - Chills
 - Fever
 - Cough
 - Body pain/
muscles aches
 - Headache
 - Loss of taste
or smell
 - Nausea or
vomiting
 - Diarrhea
 - Sore throat
 - Stuff or runny
nose
 - Tiredness
 - Trouble
breathing
 - Shortness of
breath

STUDY DESIGN

The ACTIV-2 Study will look at a number of different medicines that researchers believe are most likely to help those with COVID-19. Since most of the medications that will be tested as a COVID-19 treatment are new, ACTIV-2 will be conducted in two phases:

- Phase 2 (the first phase of ACTIV-2) will look at the safety of a medicine and whether it improves COVID-19 symptoms. This phase will involve about 220 people—half will randomly be assigned to receive the study medicine and half will receive placebo.
- If the medication is safe and seems to make people feel better or shed less virus in Phase 2, it will move to Phase 3, where about 890 more people will randomly be assigned to receive that same medicine and 890 to receive the placebo, to make certain the medicine is safe and effective, including helping to prevent hospitalization and death.

The study lasts about 6 months and involves in-person visits at a research clinic, as well as phone calls or video chats.

DO YOU HAVE ELIGIBLE PATIENTS?

If you have any eligible patients who meet the criteria for the study, please refer them to the ACTIV-2 Study.



Refer your patients to RiseAboveCOVID.org to learn more about the study or have them call 877-345-8813 to speak with a member of our team.